The TRAF2 gene (TNF Receptor Associated Factor 2) encodes a critical E3 ubiquitin ligase that serves as a central adaptor protein in TNF receptor signaling pathways. Located at chromosome 9q34.3, TRAF2 plays essential roles in regulating NF-κB signaling, apoptosis, cellular stress responses, and inflammatory cascades that are fundamental to both normal immune function and the pathogenesis of neurodegenerative diseases[1][2]. Research has increasingly implicated TRAF2-mediated signaling in Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis (ALS), and other neurological disorders, making it an important therapeutic target. The protein functions as both an adaptor molecule and an E3 ubiquitin ligase, enabling it to orchestrate complex signaling networks that determine cell survival, death, and inflammatory responses in the brain.
| Attribute | Value |
|---|---|
| Gene Symbol | TRAF2 |
| Full Name | TNF Receptor Associated Factor 2 |
| Chromosomal Location | 9q34.3 |
| NCBI Gene ID | 7186 |
| OMIM | 601985 |
| Ensembl ID | ENSG00000126933 |
| UniProt ID | Q9UAV6 |
| Protein Class | E3 ubiquitin ligase (TRAF family) |
| Aliases | TRAP, TNF-R2-associated factor, MORT1-associated protein |
| Associated Diseases | Alzheimer's Disease, Parkinson's Disease, ALS, Rheumatoid Arthritis, Cancer |
The TRAF2 protein contains several distinct structural domains that enable its diverse functions:
RING domain (N-terminus): The RING finger domain confers E3 ubiquitin ligase activity. This domain catalyzes the transfer of ubiquitin molecules to target proteins, particularly RIPK1 and other signaling intermediates. The RING domain is essential for the pro-survival functions of TRAF2 in TNFR1 signaling.
Zinc fingers: Multiple zinc finger motifs (typically 5-7) provide protein-protein interaction surfaces. These zinc fingers mediate binding to various signaling proteins and contribute to the adaptor function of TRAF2.
Coiled-coil domain (TRAF-N domain): This trimeric coiled-coil region mediates receptor binding and interactions with other TRAF proteins. It allows TRAF2 to form homotypic and heterotypic complexes with TRAF1, TRAF3, and other TRAF family members.
TRAF domain (C-terminus): The conserved TRAF domain enables trimerization and is critical for downstream signaling. This domain interacts with TNFR2, CD40, and other receptors, as well as with negative regulators.
The overall architecture allows TRAF2 to function as a molecular scaffold, assembling signaling complexes while simultaneously catalyzing ubiquitin chain synthesis.
TRAF2 exhibits two major enzymatic functions:
TRAF2 synthesizes various types of ubiquitin chains:
The ubiquitin chains generated by TRAF2 serve as signaling platforms that recruit downstream effectors bearing ubiquitin-binding domains.
Beyond its enzymatic activity, TRAF2 serves as a critical adaptor:
TRAF2-mediated NF-κB signaling is chronically activated in Alzheimer's disease, contributing to disease pathogenesis through multiple mechanisms[3][4]:
Amyloid-beta (Aβ) peptides activate NF-κB signaling through TRAF2-dependent pathways:
The role of TRAF2/NF-κB in neurons is complex:
TRAF2-mediated signaling contributes to reactive gliosis:
TRAF2 intersects with tau pathology through several mechanisms:
In Parkinson's disease, TRAF2/NF-κB signaling contributes to dopaminergic neuron loss[6][7]:
TRAF2 interacts with α-synuclein pathology:
TRAF2 dysregulation has been implicated in ALS[8]:
TRAF2-mediated NF-κB activation drives production of multiple inflammatory mediators[9]:
| Mediator | Function | Role in Neurodegeneration |
|---|---|---|
| TNF-α | Pro-inflammatory cytokine | Direct neurotoxicity |
| IL-1β | Inflammatory cytokine | Promotes tau pathology |
| IL-6 | Acute phase response | Synaptic dysfunction |
| Chemokines (CCL2, CXCL8) | Immune cell recruitment | Glial activation |
| COX-2 | Prostaglandin synthesis | Inflammatory amplification |
| iNOS | Nitric oxide production | Oxidative stress |
TRAF2 is essential for canonical (classical) NF-κB signaling:
TRAF2 also plays roles in non-canonical NF-κB signaling:
TRAF2 coordinates MAPK activation:
TRAF2 interacts with numerous proteins to execute its signaling functions:
| Interactor | Interaction Type | Functional Significance |
|---|---|---|
| TNFR1 | Receptor binding | Primary TNF signaling |
| TNFR2 | Receptor binding | Alternative TNF signaling |
| CD40 | Receptor binding | B cell activation |
| TRAF1 | Heterotrimer | Complex formation |
| TRAF3 | Heterotrimer | Negative regulation |
| c-IAP1/2 | Ubiquitination | Anti-apoptotic signaling |
| NEMO/IKKγ | Signal transduction | NF-κB activation |
| RIPK1 | Kinase binding | Cell death regulation |
| TRADD | Adaptor binding | Death domain signaling |
| A20 | Negative regulation | NF-κB inhibition |
TRAF2 is expressed in various brain cell types with distinct patterns:
| Cell Type | Expression Level | Notes |
|---|---|---|
| Neurons | Moderate | Higher in vulnerable populations |
| Microglia | High, increases with activation | Key source in inflammation |
| Astrocytes | Constitutive, increased in reactive gliosis | Major contributor to neuroinflammation |
| Oligodendrocytes | Low | May be affected in demyelination |
| Endothelial cells | Moderate | BBB function and inflammation |
Brain expression is influenced by:
Targeting TRAF2/NF-κB pathway for neurodegeneration is an active area of research[10][11]:
TRAF2 expression may serve as:
Last updated: 2026-03-26
Arch RH, Gedrich RW, Thompson JR. TRAF proteins and modulation of immune receptor signaling. Journal of Biological Chemistry. 1998. ↩︎
Bradley JR, Pober JS. TNF receptor-associated factors (TRAFs). Oncogene. 2001. ↩︎
Kaltschmidt B, Kaltschmidt C, Widera D. NF-κB in Alzheimer's disease: role in pathogenesis and therapeutic opportunities. International Journal of Biochemistry and Cell Biology. 2005. ↩︎
Chen CH, Yu HB, Lai CC, et al. TRAF2 and TNFR signaling in neurodegeneration. Journal of Neuroinflammation. 2012. ↩︎
Mondragon-Rodriguez S, Wang J, Zhang X, et al. TRAF2 in tau pathology and neurodegenerative diseases. Molecular Neurobiology. 2019. ↩︎
Ghosh A, Raza Khan M, Kumar A, et al. NF-κB in Parkinson's disease: evidence and therapeutic implications. Movement Disorders. 2019. ↩︎
Deleidi M, Hargus G, Hallett PJ, et al. Development of neuroinflammation and dopaminergic neuron loss in Parkinson's disease. Journal of Neural Transmission Supplementum. 2010. ↩︎
Wu Z, Li Y, Li H, et al. TNF receptor-associated factor 2 and ALS: genetic and mechanistic studies. Human Molecular Genetics. 2017. ↩︎
Glass CK, Saijo K, Winner B, et al. Mechanisms underlying inflammation in neurodegeneration. Cell. 2010. ↩︎
O'Neill LA, Bowie AG, O'Neill LA, et al. Targeting the NF-κB pathway for neuroprotection. Nature Reviews Drug Discovery. 2023. ↩︎
Barnes DE, Wolf MS, Kivipelto M, et al. NF-κB pathway in Alzheimer's disease: mechanisms and therapeutic targeting. Alzheimer's and Dementia. 2023. ↩︎